Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AA 673

Known as: AA-673 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1990
1990
The pharmacodynamics of Amlexanox (AA-673), an azoxanthone derivative recently developed as an ocular anti-allergic drug, were… Expand
1989
1989
The effect of amlexanox on the non-immunological or immunological release of histamine or leukotrienes (LTs) from passively… Expand
1989
1989
The inhibitory effect of 0.25% AA-673 eye drops on histamine release in tears was examined by an ocular provocation test with… Expand
1989
1989
The influences of anti-allergic drugs on superoxide generation from the hypoxanthine-xanthine oxidase system or polymorphonuclear… Expand
1989
1989
The therapeutic effect and the safety of AA-673 tablets were studied in 31 patients with intractable perennial allergic rhinitis… Expand
1988
1988
Twenty patients with perennial allergic rhinitis were treated with AA-673 tablets for a mean period of 66 days.Based on the final… Expand
Highly Cited
1987
Highly Cited
1987
Amlexanox markedly inhibits histamine release from rat mast cells. To clarify the mechanism of this inhibition, we investigated… Expand
1985
1985
Amoxanox inhibited immunologically stimulated and LTD4-induced bronchoconstriction in laboratory animals. Amoxanox, like DSCG… Expand
1985
1985
We studied the effects of amoxanox (AA-673) on allergic asthma and spasmogen-induced bronchoconstriction in guinea pigs and rats… Expand
Highly Cited
1985
Highly Cited
1985
The metabolites and degradation products of 2-amino-7-isopropyl-5-oxo-5H-[1] benzopyrano-[2, 3-b] pyridine-3-carboxylic acid… Expand